Behcet's syndrome
SR Dalvi, R Yildirim, Y Yazici - Drugs, 2012 - Springer
Behcet’s syndrome (BS) is a vasculitis, seen more commonly around the Mediterranean
and the Far East, and manifests with oral and genital ulcerations, skin lesions, uveitis, and …
and the Far East, and manifests with oral and genital ulcerations, skin lesions, uveitis, and …
Pseudo-pseudo Meigs' syndrome in a patient with systemic lupus erythematosus
SR Dalvi, R Yildirim, D Santoriello, HM Belmont - Lupus, 2012 - journals.sagepub.com
Pseudo-pseudo Meigs’ syndrome (PPMS) is a rare manifestation of patients with systemic
lupus erythematosus (SLE), defined by the presence of ascites, pleural effusions and an …
lupus erythematosus (SLE), defined by the presence of ascites, pleural effusions and an …
Scoping beyond pulmonary artery involvement; pulmonary involvement in Behcet's disease; a retrospective analysis of 28 patients
R Yıldırım, S Oğuzman, M Dinler, NŞY Bilge… - Clinical …, 2023 - Springer
Objectives Pulmonary involvement other than pulmonary artery involvement in Behcet’s
disease still remains an area of investigation. The aim of this study was to evaluate pulmonary …
disease still remains an area of investigation. The aim of this study was to evaluate pulmonary …
Approach to vaccination in systemic lupus erythematosus on biological treatment
R Yıldırım, T Oliveira, DA Isenberg - Annals of the Rheumatic Diseases, 2023 - ard.bmj.com
In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive
agents have attempted to improve the prognosis and outcome in patients with …
agents have attempted to improve the prognosis and outcome in patients with …
Reactivation in major organ involvement following SARS-CoV-2 mRNA vaccination in Behçet's syndrome patient receiving immunosuppressive therapy
R Yıldırım, D Üsküdar Cansu, M Dinler… - Rheumatology, 2022 - academic.oup.com
DEAR EDITOR, mRNA-based novel vaccines have been playing a critical role in controlling
the burden of the coronavirus disease 2019 pandemic on healthcare systems. Despite …
the burden of the coronavirus disease 2019 pandemic on healthcare systems. Despite …
Hypercalcemia in IgG4-related disease: coincidental or associated? Case based review
D Üsküdar Cansu, GB Cansu, R Yildirim… - Rheumatology …, 2022 - Springer
Immunoglobulin (Ig) G4-related disease (IgG4RD) is a chronic autoimmune disorder
characterized by dense lymphoplasmacytic infiltrations and fibrosis of storiform pattern. The most …
characterized by dense lymphoplasmacytic infiltrations and fibrosis of storiform pattern. The most …
[PDF][PDF] Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre cohort
F Guimarães, R Yildirim, DA Isenberg - Clin Exp Rheumatol, 2023 - clinexprheumatol.org
Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre
cohort Page 1 Clinical and Experimental Rheumatology 2022 Clinical and Experimental …
cohort Page 1 Clinical and Experimental Rheumatology 2022 Clinical and Experimental …
A rarely seen manifestation in Behcet's disease: intracardiac thrombosis
R Yıldırım, M Dinler, NŞY Bilge, T Kaşifoğlu - Clinical Rheumatology, 2021 - Springer
Discussion Behcet’s disease (BD) is primarily known by its mucocutaneous and ocular
manifestations [2]. However, vascular involvement in BD, which may be seen in about 40% of …
manifestations [2]. However, vascular involvement in BD, which may be seen in about 40% of …
Coexistence of IgG4-related disease and ANCA-associated vasculitis: case report and review of the literature
IgG4-related disease (IgG4-RD) is a fibroinflammatory condition that is characterized by
storiform fibrosis, infiltration of IgG4-positive lymphocytes, obliterative phlebitis, and high IgG4 …
storiform fibrosis, infiltration of IgG4-positive lymphocytes, obliterative phlebitis, and high IgG4 …
Rituximab in myositis: where are we now? A survey of current usage
T Oliveira, R Yıldırım, C Deakin, D Isenberg - Rheumatology, 2023 - academic.oup.com
DEAR EDITOR, In a retrospective analysis 7 years ago, it was estimated that 78% of patients
with inflammatory myositis were considered to have improved with rituximab (RTX)[1]. The …
with inflammatory myositis were considered to have improved with rituximab (RTX)[1]. The …